SCHEMBL680848

SCHEMBL680848

O=C(O)Nc1ccc(-c2cc3c(cnn3C3CCCCO3)cc2O)cn1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.53
RXRB P28702 1/20 0.53
RXRG P48443 1/20 0.53
CYP4F2 P78329 3/20 0.40
CYP4A11 Q02928 3/20 0.40
PIK3CD O00329 2/20 0.40
GSK3B P49841 3/20 0.36
DYRK1A Q13627 3/20 0.36
WNT1 P04628 2/20 0.36
MAPK1 P28482 2/20 0.35
MCL1 Q07820 1/20 0.34
ATR Q13535 2/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
ABL1 P00519 3/20 0.34
USP30 Q70CQ3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680700 0.86 RXRA (0.52) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL680337 0.84 RXRA (0.50) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL680086 0.81 RXRA (0.43) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL679359 0.79 RXRA (0.41) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL679358 0.79 RXRA (0.41) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30380061 0.76 RXRA (0.51) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL29000796 0.76 RXRA (0.51) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL29672462 0.76 RXRA (0.62) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL680637 0.75 RXRA (0.46) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL20437571 0.74 RXRA (0.51) RXRARXRBRXRGCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC RXRA 4592/4885RXRB 4066/4885RXRG 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.